Caffeine and neonatal acute kidney injury

Pediatr Nephrol. 2024 May;39(5):1355-1367. doi: 10.1007/s00467-023-06122-6. Epub 2023 Sep 4.

Abstract

Acute kidney injury is one of the most threatening diseases in neonates, with complex pathogenesis and limited treatment options. Caffeine is a commonly used central nervous system stimulant for treating apnea in preterm infants. There is compelling evidence that caffeine may have potential benefits for preventing neonatal acute kidney injury, but comprehensive reports are lacking in this area. Hence, this review aims to provide a summary of clinical data on the potential benefits of caffeine in improving neonatal acute kidney injury. Additionally, it delves into the molecular mechanisms underlying caffeine's effects on acute kidney injury, with a focus on various aspects such as oxidative stress, adenosine receptors, mitochondrial dysfunction, endoplasmic reticulum stress, inflammasome, autophagy, p53, and gut microbiota. The ultimate goal of this review is to provide information for healthcare professionals regarding the link between caffeine and neonatal acute kidney injury and to identify gaps in our current understanding.

Keywords: Acute kidney injury; Caffeine; Molecular mechanism; Neonatal.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / drug therapy
  • Acute Kidney Injury* / prevention & control
  • Caffeine / adverse effects
  • Central Nervous System Stimulants* / adverse effects
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Motivation

Substances

  • Caffeine
  • Central Nervous System Stimulants